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Vitamin D (VitD) deficiency is a health problem prevalent not only in the elderly but also in
young adults. The primary objective of our observational pilot study “MUVY” (Mood, UVR,
Vitamin D in Young women) was to test both the short-term and long-term effects of a series
of three suberythemal UV radiation (UVR) exposures on the VitD status and well-being of
young healthy women during winter in a repeat measure design.
Methods
20 healthy young women (Fitzpatrick skin types I–III, aged 21–25 years) received three full
body broad band UVR exposures with an escalating erythemally weighted dose schedule
during one week in winter, and completed self-report questionnaires monitoring symptoms
of depression (Beck Depression Inventory, BDI) and affective state/well-being (Profile of
Mood States, POMS) at baseline and three days after the last UVR exposure. 25-hydroxyvi-
tamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D) were measured in serum at
baseline, and at study days 8, 36 and 50.
Results
Mean baseline 25(OH)D level was 54.3 nmol/L (standard deviation (s.d.) = 24.1), with
seven women having VitD deficient status. Relevant symptoms of depression, as indicated
by low BDI total scores (0–8), were absent. After the three UVR exposures the increment of
25(OH)D was an average of 13.9 nmol/L (95% confidence interval (CI) = 9.4–18.4) and 26.2
pmol/L (95%CI = 7.2–45.1) for 1,25(OH)2D. Δ25(OH)D, and corresponding baseline levels
were significantly and inversely associated (rho = -0.493, p = 0.027). Only 25(OH)D
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remained significantly increased above baseline for at least six weeks after the last UVR
exposure. A strong inverse correlation of the POMS subscale “Vigor/Activity” and the incre-
ment in 1,25(OH)2D was found (rho = -0.739, p<0.001) at day 8.
Conclusions
Three suberythemal whole body UVR exposures during one week are a simple and suitable
method for improving 25(OH)D levels during winter, for at least six weeks, and especially in
young women with VitD deficient status.
Trial Registration
German Clinical Trials Register (Deutsches Register Kinischer Studien) DRKS00009274
Introduction
Vitamin D (VitD) is an important prohormone with numerous skeletal and non-skeletal func-
tions [1]. Both forms of VitD, cholecalciferol (VitD3) or ergocalciferol (VitD2) are biologically
inert and require an enzymatic conversion in the liver and kidney to produce its biological
active hormonal form 1α,25-dihydroxyvitamin D (1,25(OH)2D). Of note is that more than 35
additional VitD metabolites are formed by the body with possible biological functions [2–4].
Worldwide studies have shown that VitD deficiency occurs frequently across a wide range
of populations and age groups [5] (compare [6] for German population). VitD deficiency is
thought to be associated with autoimmune diseases, and the increased risk of developing
hypertension and depression [7–11]. The causality of this relationship is not clear [12]. A num-
ber of mechanisms underlying the link between VitD deficiency and depressive disorders in
adults have been proposed [13–16]. To date, the efficacy of VitD supplementation for prevent-
ing onset of depressive disorders or for reducing depressive symptoms remains insufficiently
studied [12, 17–20].
Solar ultraviolet-B radiation reaching the Earth's surface (290–320 nm) is known to initiate
VitD production in the skin, but also holds the risk of causing skin damage and carcinogenesis.
Therefore, the recommendation for limiting summer sunlight exposure in order to prevent
skin cancer may conflict with the need to have optimal VitD levels. On the other hand, because
the cutaneous synthesis of VitD can provide 90% of the physiological supply [21], it is of inter-
est that a number of experimental studies have provided data on the significance of dose, spec-
trum of UVR, area of irradiated body surface and skin pigmentation for VitD production and
25(OH)D levels in plasma [22–39]. Notably, a six-week study by Bogh et al. (2012) showed
that full body narrow band UV-B exposure three times per week is more effective in treating
VitD deficiency than a daily oral intake of 40 μg VitD3 [40].
Based on these observations, our pilot study performed on healthy young women during
the winter months aimed to investigate the short-term and long-term effects of just three sub-
erythemal UVR exposures on the serum levels of 25(OH)D, and its biologically active metabo-
lite 1,25(OH)2D. 25(OH)D is the predominant circulating form of VitD, and is generally
considered to be the best marker of VitD status [41].
25(OH)D has far less biological activity than 1,25(OH)2D, which is formed mainly in the
kidney, but also in other tissues and organs. According to Lips (2007), 1,25(OH)2D is not suit-
able as a mean of assessing VitD status, because it keeps within reference limits as long as
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possible by a hormonal regulation [42]. Thus far, circulating 1,25(OH)2D levels have received
relatively little attention, and previous studies of UV-induced VitD production have rarely
included plasma 1,25(OH)2D in their assessments. Nevertheless, in subjects with VitD defi-
ciency, the formation of 1,25(OH)2D may be limited because of reduced substrate availability
for the 1α-hydroxylase (CYP27B1) in the kidney [43].
Previous studies of UV-B induced VitD production in the skin of relatively healthy subjects
have not addressed the question as to whether UVR exposure during the winter months may
also influence mood and well-being. Therefore, the secondary aim of our MUVY pilot study was
to measure these possible effects by using standard self-rating questionnaires before and after the
three UVR exposures. We hypothesized that just three suberythemal UVR exposures within one
week would improve VitD status not only acutely but also for a longer time, and also, that the
changes observed could be associated with positive effects on affective state and functioning.
Our pilot study was conducted in order to test the feasibility of procedures and assessments for
later use in a subsequent larger research project. It should also generate important findings regard-
ing the safety of the UVR dose selected for whole body irradiation with our device, response effects
and variance of these effects as well the suitability of the self-report questionnaires selected.
At the time the MUVY pilot study was designed and performed, the results of another study
were published, finding that a significant increase in 25(OH)D can be achieved with a very low
UV-B dose [30].
Methods
The MUVY pilot study was part of a larger research project, entitled “Vitamin D3 synthesis in
the skin under different conditions of UV radiation (spectrum, radiation intensity, dosage, skin
area) taking into account radiation protection requirements and application of sunscreens”
(compare S1 and S2 Files) which was approved by the Ethical Committee of the Charité-Uni-
versitätsmedizin Berlin on the 17th of February 2009 (EA1/026/09). The study protocol con-
forms to the ethical guides of the 1975 Declaration of Helsinki. Participants of the pilot study
were recruited via advertisements posted at Berlin universities. Participants were informed
about the goals and procedures of the pilot study, and gave written informed consent prior to
enrolling. They were also paid for their participation.
The sample size required for a pilot study depends upon the balance between the level of
precision that can be achieved and the costs incurred through data collection [44]. Adapted
from the description by Johanson and Brooks [45], we calculated that a sample size no larger
than between 10 and 20 would be appropriate for our pilot study with a repeated measure
design, if the expected effect sizes for 25(OH)D increase (Cohen’s dz) would be between 1.0
and 0.7 with a correlation coefficient between repeated measures of 25(OH)D levels between
0.8 and 0.7.
This trial is registered at the German Registry for Clinical Trials (Deutsches Register Kli-
nischer Studien): Registration Number (DRKS00009274) and URL (http://www.drks.de/
DRKS00009274).
A TREND check list for nonrandomized trials is attached in supplemental file (S2 Chart,
TREND check list).
The authors confirm that all related trials for this intervention will be registered.
Study participants
The study participants underwent evaluation and management at the Charité-Universitätsme-
dizin Berlin, Department of Rheumatology and Clinical Immunology. 20 healthy female uni-
versity students (aged 21–25 years) were included and examined in the winter months of
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December 2011 to March 2012, when daily solar UV-B radiation is minimal to negligible in
Berlin, Germany (Latitude: 52° N) [46].
Subjects were screened for medical and psychological health via questionnaires and inter-
views, and were excluded if they had known dermatological, hepatic, renal or psychiatric disor-
ders, namely depressive disorders, known inadequate reactions to sunlight (such as solar
urticaria, polymorphic light eruption or photodermatitis), regularly took VitD supplementa-
tion or possibly photosensitizing medication, had recently visited sunnier countries or under-
gone solarium tanning, or were aged over 30 years. Only Caucasian women of Fitzpatrick skin
types I, II and III living in Berlin were included. Of the initially interested 30 volunteers, 10
were not included due to either their taking of Vitamin D supplementation, having a history of
inadequate reactions to sunlight and/or being Fitzpatrick skin type IV.
Procedure and Irradiation
The UV source was an approved phototherapeutic device for whole-body irradiation (Wald-
mann GmBH and Co, Germany, type GH-8 ST) fitted with eight broad-band UV fluorescent
tubes, type ARIMED B1 (100 W). The output of the tubes over the entire UV band from 250
to 400 nm is composed of 8% UVB (280–320 nm) and 92% UVA (320–400 nm) [47]. Within
the spectral range of UV-B the spectral slope of emission of these tubes was approximately
comparable to the spectral slope of solar irradiance at the Earth’s surface during noon-time in
summer in central Europe and under a cloudless sky.
Spectral irradiance emitted by the device was measured at the center of the area of skin
exposure, and at a distance from the radiation output window which equaled the distance at
which the skin of the volunteers was exposed. The measurements were performed in the spec-
tral range 250–400 nm, with a spectral resolution of 1 nm and spectral steps of 1 nm, using a
double-monochromator spectroradiometer (type: OL 754, Optronic Inc., Orlando, Fl., USA).
This was equipped with an Ulbricht sphere as the optical head. Before starting the measure-
ment, the spectroradiometer was calibrated using a mercury fluorescent lamp to correct the
wavelength shift, and a 200 W tungsten halogen standard lamp traceable to NIST. Erythema
effective irradiance at the target distance of 39 cm was calculated to be 0.37 Wm-2 by weighting
spectral irradiance data with the CIE erythema action spectrum and subsequent integration
over the full spectral range measured [48]. This value was used to calculate the exposure times
required to obtain UV doses as defined in our exposure schedule.
The dose schedule for UVR exposures in our study was in line with the recommendations of
the UV radiation protection decree of the Federal Government of Germany [49]. All partici-
pants had three UV sessions with whole body exposure (90% of the body surface area) within
one week at one day intervals. The radiation dose was expressed in units of the (erythemally
weighted) Standard Erythema Dose (1 SED = 100 J/m2).[48].
As the individual Minimal Erythema Doses (MED)s for broad band UVB of our study partici-
pants were not known, we started with low UV doses for safety reasons: 0.8 SED was the initial
dose for women with skin type I (n = 2) and 1.0 SED for women with skin types II and III (n = 18).
If the skin inspected 24 hours after exposure showed no erythema the dose was increased to 1.2
SED for skin type I, and 1.5 SED for skin types II and III on study day 3. On day 5 the participants
were exposed to a UV dose of 1.5 SED for skin type I and 1.875 SED for skin types II and III.
Blood samples for VitD assays were obtained before the first UVR exposure (day 1) and
three days after the last UVR exposure (day 8), then at days 36 and 50 (4.5 and 6.5 weeks after
the last UVR exposure, respectively).
All 20 subjects completed the one week course of UVR exposures including day 8 assess-
ments. 16 attended all follow-up examinations. Three women were absent for the day 36
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follow-up blood sample, one of which was also absent for day 50. Another subject was absent
as well on day 50. This was due to an inability to comply with scheduled visits.
The first date of enrollment was the 5th of December 2011. All data (including blood works
results) was obtained by the 30th of May 2012.
Assessments
Estimation of skin type. To obtain a homogeneous group of women with respect to the
skin photo type, we used the self-rating scale recommended by the UV radiation protection
decree of the Federal Government of Germany [49]. This scale is similar in eight of the ten
items to the Fitzpatrick skin type questionnaire: genetic disposition (color of eyes, hair, skin,
existence of freckles) and reaction to sunlight (reaction of skin in general and facial skin to sun-
light, degree of getting tanned) [50, 51]. The Fitzpatrick category „tanning habits”was replaced
by questions on disposition for developing erythema [49].
Nutritional VitD intake status. All possible VitD containing food items in the “Ger-
man Food Propensity Questionnaire” (GFPQ) of the German Institute of Human Nutrition
Potsdam-Rehbrücke (DiFe, Deutsches Institut für Ernährungsforschung) were presented
to the subjects, who were asked to specify the amount of these food items they consumed
on average (for example “How many portions of fatty fish do you eat?”, with the options:
“never”to “three times per week and more“) [52]. Portion sizes were defined using the
AID (information service on nutrition, agriculture and consumer protection) chart of aver-
age portion sizes [53]. After converting frequency of consumed food portions into grams
per day, the daily VitD intake was calculated using a nutritional content online calculator
[54].
Assessment of affective state and well-being. To quantify affective state and levels of
well-being, the study participants completed both questionnaires, at baseline, and three days
after the last UVR exposure (study day 8):
The Beck Depression Inventory (BDI) was originally designed to measure the presence
and intensity of typical symptoms of depression in patients who have already been diagnosed
by a psychiatrist according to standard criteria. The BDI consists of 21 items that assess affec-
tive, cognitive and somatic symptoms of depression, rated on four-points scales.
The BDI is considered an adequate tool for ruling out clinically significant depressive disor-
ders in different medical conditions [55, 56]. We applied the conventional cut-offs for classifi-
cation of BDI scores into non-depressed (under 11) and depressed (11 or higher).
The Profile of Mood States (POMS), in its original version, is a 65-item inventory designed
for use with adult psychiatric outpatients, which monitors affective state, levels of functioning,
and subjective well-being [57]. The POMS assesses six dimensions of the mood construct:
anger, confusion, depression, fatigue, tension, and vigor. In addition, “total mood disturbance”
can be calculated by subtracting the Vigor subscale score from the sum of the tension, depres-
sion, anger, confusion, and fatigue subscale scores.
At present, there are varied short forms of the POMS in use. In the MUVY study, we used
the well-validated German short form of the POMS [58]. It consists of 35 items measured on a
0-4 numerical rating scale with only four subscales (depression/anxiety, fatigue, hostility and
vigor/activity). All participants were asked to rate “How are you feeling right now?” in terms of
the 35 mood descriptions. According to the original version we focused on the calculation of
the “total mood disturbance” score, by subtracting the vigor subscale score from the sum of the
depression/anxiety, fatigue and hostility subscale scores. Thus, negative POMS total scores
indicate the predominance of the vigor/activity subscale over the other subscales, whilst posi-
tive scores represent “mood disturbances” of different severity.
MUVY Pilot Study
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As indicated by low BDI scores at baseline, our study participants who received UVR were
not classified as suffering from major or minor depression.
Blood collection and biochemical assessments. Venous blood samples (10 ml) were col-
lected into Vacutainer1 tubes without anticoagulants between 4 and 6 p.m., and stored for
one hour at room temperature to ensure complete clotting. After centrifugation according to
standard procedures, aliquots of serum were kept at -80°C until assayed. After the study was
finished, all serum samples were analyzed in one batch adhering to standard operating proce-
dures at our hospital laboratory for clinical chemistry with external quality control (Labor Ber-
lin–Charité Vivantes Service). The laboratory uses a new generation of automated,
chemiluminescence-based immunoassays of 25(OH)D and 1,25(OH)2D (IDS-iSYS 25(OH)D
and IDS-iSYS1,25(OH)2D, Immunodiagnostic Systems, Ltd, Boldon, UK).
The measurement range of these assays is 15–315 nmol/L for 25 (OH)D and 18–504 pmol/
L for 1,25(OH)2D (information of the manufacturer). The IDS-iSYS control sets were used for
quality control.
Although there is no universally accepted definition of VitD deficiency, insufficiency or
optimal status, we classified our participants according to serum 25(OH)D concentrations cat-
egorized into three groups:<50 nmol/L (deficient); 50-75 nmol/L (insufficient), and>75
nmol/L (optimal) [41]. Generally, 25(OH)D levels>75 nmol/L are considered desirable for
fracture prevention [59].
1,25(OH)2D levels between 50.4 pmol/L and 245 pmol/L are given as the specific reference
range by the laboratory conducting our analyses [60].
Adverse Events (AEs). Although suberythemal UVR exposures should not be associated
with adverse skin effects, the participants were invited to complete AE forms during this trial.
The following AEs such as dizziness, dry skin, erythroderma, pain of skin, occurrence of ery-
thema (different grades), pruritus, skin atrophy, urticaria, and nausea were classified according
to the “Common Terminology Criteria for Adverse Events” (CTCAE) version 4.0, and inten-
sity, duration, and applied measures for improvement were noted [61]. Assessment of addi-
tional, unlisted AEs was possible and encouraged.
Statistical analyses
Data was analyzed using the statistical software package SPSS 18.0 (SPSS Institute, Chicago,
USA). Descriptive statistics were inspected for normal distribution of variables using the Kol-
mogorov-Smirnov test, homogeneity of the variance (Levene-test) and outliers. The results are
presented as mean±standard deviation (s.d.) or median.
Continuous variables were compared using the paired Student’s t-test or Wilcoxon test for
repeated measures. Whilst also controlling for putative confounders such as the use of oral con-
traceptives, skin type and daily dietary VitD intake, we also employed univariate general linear
models (GLM) for the baseline 25(OH)D and 1,25(OH)2D levels. Because we measured the
same variables on several occasions for each subject, we also used GLM for repeated measures
with a within-subject factor (the number of repetitions, specified as study day) and with the
between-subject factors—skin type and use of contraceptives [62]. These factors were selected
based on their possible association with the investigated VitD measures shown in previous
studies. In this model, a conservative measure of significance was used (p0.01) if the assump-
tion of variance homogeneity in all cells was violated. Due to missing VitD measures in the fol-
low-up in some study participants, the procedure GLM for repeated measures was applicable
for the 16 women with complete data sets.
Relationships between outcome measures were explored using Spearman correlation.
MUVY Pilot Study
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In most of the calculations all participants were analyzed as an entire group. For examining
the UV-induced increase of 25(OH)D and 1,25(OH)2D depending on the VitD status at base-




The demographic and psychometric characteristics of the study group at baseline including
age, BMI, use of oral contraceptives, smoking status, daily intake of VitD, BDI and POMS
score are reported in Table 1.
All women scored low on the BDI, with scores ranging from 0–8. The mean POMS total
score indicated good well-being und functioning. Fitzpatrick skin types II and III were repre-
sented in 90% of the participants.
Table 2 shows the baseline mean total serum levels of 25(OH)D and 1,25(OH)2D. Looking
at individual values, seven of the 20 participants had a VitD deficiency, with 25(OH)D levels
below 50 nmol/L, and twelve an insufficiency with concentrations between 50 and 75 nmol/L.
The daily VitD intake correlated moderately with baseline 1,25(OH)2D concentration (n = 20,
rho = 0.458, p = 0.042), but not with the 25(OH)D concentration (n = 20, rho = 0.088,
p = 0.712).
To explain this variance in baseline 25(OH)D and 1,25(OH)2D by possible confounds such
as the use of oral contraceptives, skin type (as factors) and daily nutritional VitD intake (as
covariate), we used the GLM. In this model, only a significant main effect of oral contraceptives
(F = 6.714, df = 1, p = 0.018) was observed for 1,25(OH)2D but not for 25(OH)D. Post hoc
analysis indicated that women using oral contraceptives (n = 12) had higher average 1,25
(OH)2D levels at baseline (145.8±31.6 vs. 108.6±31.1 pmol/L, T = -2.591, p = 0.018), but similar
25(OH)D values (57.4±27.4 and 50.0±18.8 nmol/L).
Interestingly, BDI baseline values correlated moderately and negatively with baseline concen-
trations of 1,25(OH)2D (n = 20, rho = -0.597, p = 0.005) and of 25(OH)D (n = 20, rho = -0.542,
p = 0.013), whereas both VitD metabolites were not correlated (rho = 0.333, not significant).
UVR effects on Vitamin D status
A low cumulative erythemally weighted dose of UV irradiation of 3.5 SED within one week
was given to only two participants (skin type I). The remaining 18 women (skin types II and
Table 1. Baseline characteristics of subject group.
n = 20
age (years) 23.0±1.2 [21–25]
BMI (kg/m2) 21.2±2.6 [17.5–27.7]
oral contraceptives, % (n) 60% (12)
smokers, % (n) 10% (2)
Fitzpatrick skin types I /II/III (n) 10% (2)/30% (6)/60% (12)
daily dietary VitD intake (μg/d) 3.0±2.2 [0.7–10.0]
baseline BDI total score 4.0±2.1 [0–8]
baseline POMS total score 0.5±14.3 [–15–49]
n, number; s.d., standard deviation; BMI, body mass index; VitD, Vitamin D; BDI, Beck Depression Inventory;
POMS, Proﬁle of Mood States; absolute values are given as mean±s.d. [range]
doi:10.1371/journal.pone.0159040.t001
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III) were subjected to a cumulative dose of 4.375 SED. Overall, after the three UVR exposures,
a significant increase in 25(OH)D and 1,25(OH)2D levels was observed at study day 8
(Table 2). Individual courses of 25(OH)D levels throughout the study are shown in Fig 1. Only
the single participant with an ideal level at baseline did not experience an increase after UVR
exposures (Fig 1). Whereas the mean serum level of 25(OH)D at day 36 and 50 (31 and 45 days
after the final UVR exposure) remained significantly higher versus baseline, the concentration
of the biologically active metabolite 1,25(OH)2D decreased significantly from day 8 to day 36.
At day 50 it was slightly lower than the baseline value (paired t-test versus baseline, Table 2).
GLM for repeated measures (n = 16 women with complete data sets), controlling for skin
type, confirmed the significant effect of UVR exposures on 25(OH)D; in the pairwise compari-
sons the difference versus baseline was significant at day 8 (p = 0.004) and day 36 (p = 0.020),
but not at day 50 (p = 0.957).
Notably, the increment of 25(OH)D concentrations above baseline after the three UVR
exposures was moderately negatively correlated with the baseline 25(OH)D levels (rho =
-0.493, p = 0.027) (Fig 2). Therefore, as expected, a better response (increase in 25(OH)D) was
achieved in participants with the lowest baseline 25(OH)D values. In the deficient subjects
(<50 nmol/L), increase in 25(OH)D was twice as high (Δ 21.2±10.3 nmol/L) as in the others (Δ
10.0±6.6 nmol/L). Accordingly, this subgroup also showed an average higher increase in 1,25
(OH)2D levels at day 8 (Δ 45.1±44.4 vs. Δ 15.9±35.7 pmol/L).
Psychometric measures
There was no correlation between the BDI and POMS total scores (rho = 0.099) at baseline, but
a low and significant correlation between the two scales was found at day 8 (rho = 0.446,
p = 0.049).
The mean BDI total score decreased significantly from baseline to study day 8 (Table 3).
There was a significant moderate inverse relationship between BDI total score and 1,25
(OH)2D or 25(OH)D levels at baseline (rho = -0.597, p = 0.005 and rho = -0.542, p = 0.013,
respectively), but not at day 8 (rho = -0.181 and rho = -0.173, respectively).
Table 2. 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D at baseline, day 8, day 36, day 50 and change from baseline.
baseline (n = 20) day 8 (n = 20) day 36 (n = 17) day 50 (n = 18)
25(OH)D, nmol/L mean±s.d. 54.4±24.1 68.3±18.2 62.0±22.8 60.3±21.6
Median 54.7 67.0 62.4 63.1
Range 12.5-122.1 43.7-119.3 24.0-125.0 22.3-116.5
Δ CfB 13.9±9.5 8.8±8.4 5.2±10.0
95% CI 9.4 to 18.4 4.5 to 13.1 0.2 to 10.1
p value* <0.001 0.001 0.044
1,25(OH)2D,pmol/L mean±s.d. 130.9±35.8 157.1±49.8 129.8±44.9 125.7±33.3
Median 138.5 167.0 125.0 118.0
Range 71-201 78-236 38–208 71–182
Δ CfB 26.2±40.4 -7.1±33.2 -11.0±36.6
95% CI 7.2 to 45.1 -24.2 to 9.9 -29.2 to 7.2
p value* 0.009 0.39 0.22
25(OH)D, 25-hydroxy vitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; s.d., standard deviation; CI, conﬁdence interval; CfB, change from baseline
*p values for the paired t-test versus baseline; n, number; Δ, delta
doi:10.1371/journal.pone.0159040.t002
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Fig 1. Individual Vitamin D status as expressed by 25-hydroxyvitamin D concentration in plasma during the study
doi:10.1371/journal.pone.0159040.g001
MUVY Pilot Study
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Next, we analyzed the data from POMS. The mean POMS total score was similar at baseline
and day 8 and indicated good well-being and functioning (Table 3). There were also no signifi-
cant changes for the subscales of POMS (Table 3). However, POMS total score three days after
the final UVR exposure, and the increment of 1,25(OH)2D, correlated moderately and signifi-
cantly at this time point (rho = 0.549, p = 0.012). This relationship was mainly due to the
POMS subscale vigour/activity. Vigour/activity subscale scores at day 8 and increment in 1,25
(OH)2D were strongly and inversely correlated (rho = -0.739, p<0.001) (Fig 3).
Fig 2. Scatterplot diagram, relationship between increase in 25-hydroxyvitamin D at day 8 and baseline 25-hydroxyvitamin D levels
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Adverse events
The first two irradiations were tolerated without the occurrence of AEs. After the third and last
UVR exposure one participant experienced skin dryness, another skin pain, and three mild
redness. These AEs were reported as occurring between 1–2 hours after the last UVR exposure.
Two of the three women with diffuse mild redness without defined borders were of skin type
II, and one was skin type I. All of the symptoms disappeared within the same evening and no
remedial measures were required. Other possible adverse events were not reported. Therefore,
the short-term mild skin redness in three women after the last UVR was not classified as an
UV-B induced erythema.
Discussion
The first main finding of the MUVY pilot study was that just three serial escalating UVR expo-
sures to whole body area during one week were sufficient in increasing 25(OH)D and 1,25
(OH)2D total levels in the circulation of young healthy Caucasian women with sun-reactive
skin types I–III, and the second was that these effects remained significant for at least six weeks
after the last UVR exposure for 25(OH)D (Table 2).
Although we have not pre-examined the individual erythema threshold doses in our study
participants for the device used, our schedule to start the whole body UVR exposure with 0,8
SED for skin type I and 1.0 SED for skin types II and III was reliable in avoiding unwanted
acute skin reactions such as erythema. Only after the third and last UVR exposure with 1.5
SED (skin type I) or 1.875 SED (skin types II–III) did five women report adverse events such as
skin dryness, skin pain or mild skin redness; all of the symptoms disappeared within the same
evening. With respect to the short-time mild skin redness in three women, we would like to
assume that this effect cannot be considered as a classical UV-B induced erythema.
Table 3. BDI and POMS scores at baseline and day 8.
baseline (n = 20) day 8 (n = 20) Wilcoxon test
BDI score mean±s.d. 4.0±2.1 2.6±2.5 Z = -2.386p = 0.017
range 0–8 0–11
median 4.0 3.0
POMS total score mean±s.d. 0.5±14.3 -0.45±13.2 Z = -0.503p = 0.615
range -15-49 -14-34
median -2.0 -5.0
POMS depression/anxiety mean±s.d. 3.4±5.8 3.6±5.9 Z = -0.143p = 0.886
Median 1.0 1.0
Range 0–26 0–24
POMS vigor mean±s.d. 10.5±4.7 11.6±4.4 Z = -1.009p = 0.313
Median 10.0 12.0
Range 3–20 3–21
POMS fatigue mean±s.d. 5.3±3.9 5.0±4.4 Z = -0.415p = 0.678
Median 5.5 4.5
Range 0–16 0–16
POMS hostility mean±s.d. 2.4±4.6 2.7±2.9 Z = -1.249p = 0.212
Median 1.0 1.5
Range 0–20 0–9
BDI, Beck Depression Inventory; POMS, Proﬁle of Mood States; s.d., standard deviation; n, number
doi:10.1371/journal.pone.0159040.t003
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Overall, our pilot study showed that for the planning of further research on VitD response
to broad band UV-B radiation in young Caucasian women with skin types II–III, an escalating
dose schedule for the whole body exposure with a low initial dose and a maximum dose not
exceeding 1.875 SED may be considered, practicable and sufficient to induce VitD synthesis in
the skin, whilst avoiding unnecessary skin reactions like erythema and tanning. For compari-
son, in the study by Bogh et al.(2011) four broad band UVB exposures were given in 2 to 3 day
intervals to the chest and back (24% body surface area) of 55 selected healthy subjects with
baseline 25(OH)D levels50 nmol/L and Fitzpatrick skin types I–IV [30]. The UVB doses
tested were between 3.0 and 0.375 SED, with the most pronounced effect on 25(OH)D increase
in the group exposed to 3.0 SED. 20% of the study participants in this group developed
erythema.
Fig 3. Scatterplot diagram, relationship between POMS subscale Vigor/Activity and the increment in 1,25-dihydroxyvitamin D at day 8 (linear
regression analysis, r2 = 0.445, p<0.001). The solid line is the linear fit and dashed lines are the 95% confidence limits to the fit.
doi:10.1371/journal.pone.0159040.g003
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An important issue is determining the frequency and number of UVR exposures necessary
during winter to prevent a decline of summer VitD levels and/or to maintain these levels as sta-
ble throughout the year. Bogh et al. (2012) explored the effect of a fixed UV-B dose of 1.0 SED
applied every second week to 88% body area in 14 healthy subjects (mean age 36 years) during
a period of four months, and found that this procedure is sufficient to maintain summer 25
(OH)D concentrations through winter time, whereas the same procedure performed once a
week even resulted in significant increases in 25(OH)D levels [31]. On the other hand, Farrar
et al. (2011) showed that in 109 Caucasian non-elderly adults from Greater Manchester, UK,
with sun-reactive skin types I–IV (individual erythema thresholds between 1.6 SED and 8.2
SED) exposed to a constant UVR dose (1.3 SED) at January/February using a whole body irra-
diation cabin (three times weekly for 6 weeks), the weekly gain in mean 25(OH)D levels
steadily decreased with only marginal changes in weeks 4, 5 and 6 [36].
In the MUVY pilot study, we found a mean increase in 25(OH)D of 13.9 nmol/L (from
baseline to study day 8). This is comparable to effects observed in other UVR exposure studies
using fixed doses once per week for two months [23] or four months [31].
Like in the target population of young adults [63], a high rate of VitD de-/insufficiency was
detected in the MUVY study participants. Whilst there is debate as to whether skin pigmenta-
tion may influence the UVB induced VitD synthesis [64], other studies have shown that the
increment of 25(OH)D in serum after UV-B exposures depends upon baseline 25(OH)D levels
[65]. In accordance with the data of this literature, we observed a negative correlation between
baseline 25(OH)D levels and its increase after the three UVR exposures (Fig 2). Therefore, as
expected, a better response (stronger increase in 25(OH)D) was achieved in participants with
the lowest baseline 25(OH)D values. In our subgroup of 7 women with deficient VitD status 25
(OH)D increased from baseline to day 8 by 21.2 nmol/L. Therefore, we can assume that already
a small number of whole body suberythemal UVR exposures in winter could improve VitD sta-
tus, especially in women with VitD insufficiency.
In general, published UVR studies have not conducted follow-up examinations of VitD
after the UVR exposures were terminated. However, we are interested in the question of
whether the initial rise of 25(OH)D and 1,25(OH)2D in response to UVR exposures can be
maintained for a longer time (>4 weeks), or subsequently declines after the treatment has been
terminated. Our finding of long-term UVR effects only on 25(OH)D levels in serum (Table 2)
may be explained by the fact that its active form 1,25(OH)2D has a short half-life of less than
one day compared to three weeks for 25(OH)D [66]. 25(OH)D is fat soluble and storable, and
therefore represents a steady VitD state derived from dietary intake and UVR-assisted self-pro-
duction of the last weeks and months [66]. In this respect, it is notable that after a single VitD3
dose of 100,000 IU, serum levels of 25(OH)D peaked at day 7 and fell slowly to baseline values
by day 112 [67].
The possible influence of oral contraception on VitD levels was examined in several studies,
mainly observing higher VitD levels in women using oral contraceptives [68–71]. In the
MUVY study, women with oral contraceptives showed significantly higher 1,25(OH)2 baseline
levels. Genetic polymorphisms in the VitD receptor and increased levels of VitD binding pro-
tein seem to play a role [70, 72].
To our knowledge there are no systematic studies investigating the effects of UVR exposures
on the VitD status, and different aspects of well-being in patients with clear psychiatric diagno-
sis of major/minor depression or seasonal affective disorder but without medical comorbidity
in parallel. On the other hand, differences in reported findings in studies with VitD supplemen-
tation in patients with depression are likely not only to be affected by study population and
dosage schemes, but also by choice of diagnostic criteria, screening tools and self-report
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questionnaires used. In our opinion, the choice of a suitable self-rating test to detect possible
mood changes seems to present a problem.
Therefore, we are also interested in the question of whether UVR exposures in winter
months may influence the affective state/well-being of healthy women outside of symptoms/
behaviors which are typical for depressive disorders. Recent or past major and minor depres-
sion, according to the DMS IV (Diagnostic and Statistical Manual of Mental Disorders) crite-
ria, was an exclusion criterion of the pilot study. Our study participants had a low mean BDI
total score at baseline, which decreased further significantly at day 8 (Table 3). We abstain
from interpreting this statistically meaningful result as a clinically significant effect of UVR
exposure on depression, since our healthy subjects did not suffer from depressive disorders. On
the other hand, associations between improved VitD status by VitD3 supplementation and
decrease in BDI total scores, as a measure of depressive symptoms, have been assumed in the
frequently cited pilot study by Shipowick et al. [18]. In this study, six women with VitD defi-
ciency and high scores on the BDI-II (range 26–40) completed eight weeks of VitD3 supple-
mentation (5,000 IU/day) [18]. As no significant correlations between BDI-II total score and
25(OH)D serum levels at baseline or after the treatment were found, it is questionable whether
a causal relationship exists between the improvement of VitD status and the observed reduc-
tion in the severity of depressive symptoms. Medical and psychiatric conditions or medication
used by the participants were not sufficiently reported in this study [18].
Our sample of women with good well-being und functioning, despite the majority having
low 25(OH)D levels, have limited our ability to detect expected positive effects of UVR expo-
sure on the affective state. The BDI does not seem to be a suitable instrument for measuring
these changes if the study participants are of generally good mental health. On the other hand,
POMS as an adjective rating scale which has been used in prospective studies of mood changes
both in psychiatric out-patients and subjects without psychiatric conditions could be a helpful
psychometric instrument [17, 73].
As indicated by the mean POMS total scores at baseline and day 8 (Table 3), our study
group as a whole was in a well-balanced affective status. Nevertheless, our finding of significant
positive correlation between POMS total score at day 8 and Δ 1,25(OH)2D seems to indicate
that acute changes in biologically active metabolite 1,25(OH)2D could impact upon well-being.
Moreover, of all POMS subscales, only vigor/activity was strongly and inversely associated with
Δ 1,25(OH)2D. Thus, as shown in Fig 3, women with a large increase in 1,25(OH)2D were less
vigorous. The interpretation of this finding is difficult. Most VitD and UV-B exposure studies
only analyze changes in 25(OH)D, and not in 1,25(OH)2D [22–39]. Given the interaction of
1,25(OH)2D with membrane-based signaling pathways in different cell types [74], as well as
the existence of numerous additional VitD metabolites with possible biological activity [2–4], a
simple causal relationship should not be assumed. Furthermore, it should also be taken into
consideration that the production of neuroactive factor classes other than VitD related com-
pounds is also affected by UVR. Aside from immunoregulatory molecules, neuropeptides, neu-
rotrophins, and neurotransmitters, the CRH-POMC-system (corticotropin-releasing hormone
—Pro-opiomelanocortin—system) for example is strongly influenced and regulated by UVR
[75].
One important limitation of the MUVY pilot study was that the second assessment of mood
and well-being was performed three days after the final UVR exposure. This may have limited
our ability to detect potential acute effects of UV irradiation on psychometric measures in
healthy young women without clear symptoms of depressed mood or impaired functioning.
Notably, most study participants reported spontaneously feeling better after the UVR sessions
(less fatigued, more relaxed). Another limitation was that Parathyroid hormone was not mea-
sured in this pilot study, but this will be assessed in the subsequent trial.
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In summary, we suggest that our findings point to three conclusions
1. The pilot study on healthy young women with predominantly Fitzpatrick skin types II and
III showed the feasibility of our schedule with three escalating suberythemal UVR exposures
to improve the VitD status not only acutely but also for a longer time, as all twenty partici-
pants received every predefined UVR without significant adverse skin reactions.
2. The MUVY pilot study expands the literature on 25(OH)D and/or 1,25(OH)2D levels in
serum of apparently healthy subjects in response to different UVR exposures using a device
fitted with fluorescent tubes which produces an UVR emission spectrum similar to that of
sunlight, by showing that three suberythemal UVR exposures within one week during win-
ter with a dose regime of 1.0–1.5–1.875 SED for women with skin types II and III and 0.8–
1.2–1.5 SED for women with skin type I was effective in improving VitD status especially in
women with deficient 25(OH)D levels, and in maintaining this effect over a period of at
least 6 weeks in the absence of further UVR exposures.
3. Our sample of women with good well-being und functioning despite the majority having
low 25(OH)D levels have limited our ability to detect clear positive effects of UVR exposure
on the affective state. The BDI seems insufficient as an instrument for measuring these
changes if the study participants are of generally good health. As indicated from our find-
ings with POMS, the possible relationship between psychometric measures and VitD
metabolites is less simple than frequently assumed.
Our pilot study showed good feasibility in terms of most of the procedures and assessments
used. In subsequent larger research projects the schedule may be practicable for investigating
the influence of skin type on the acute and long-term effects of UVB on VitD status, including
1,25(OH)2D assessments as well as questionnaires for affective state/well-being in the research
program. For possible future application of UVR, for example, in patients suffering from rheu-
matoid arthritis, a limited number of UVR exposures within one week appears more practical
than several weeks of exposure, and might ensure greater compliance. The six-week study of
Bogh et al. (2012) with three UVR exposures per week reported a high rate of drop-outs [40].
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